Respira, United Therapeutics deal

Respira granted United Therapeutics exclusive, North American rights to RT234 to treat pulmonary hypertension. United Therapeutics will provide funding to Respira to develop RT234 through approval and United Therapeutics will be responsible for commercialization. The product is currently in preclinical testing. United Therapeutics was also the lead investor in Respira's series B financing, which closed April 11. Sun Mountain Capital and Cottonwood Technology Fund also participated. Respira declined to disclose further financial details and United Therapeutics did not respond to inquiries...